Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Uncover the best ways to sell your crafts for money and maximize your profits. Let your creativity pay off in no time!
19,146 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
As Commvault shares dive, a fresh $19.8 million stake signals confidence from a hedge fund with a plan. Here's how to...
When sandisk stock just popped, traders watched for AI data-center demand and memory-market signals. This article bre...
A hypothetical spacex stock $2.5 trillion valuation invites big questions about revenue, profitability, and risk. Thi...
If you think it's late Vertiv, you're not alone. Yet the data-center and AI infrastructure cycle still offers upside....
Palantir is venturing into a new market via Polymarket, sparking questions about its AI growth path. This guide lays ...
As AI workloads surge, choosing the right infrastructure partner matters. This guide compares CoreWeave and Nebius, w...
Tesla's Q2 delivery figures offer a clear window into demand trends and pricing power. This guide breaks down what to...
When high-growth fintech names stumble, markets react quickly. This piece breaks down Klarna’s Q4 miss, the stock mov...
What happened in Designer Brands (DBI) 2025 earnings, and what it means for investors in 2026. This guide breaks down...
So-Young's Q1 2026 results offer clues about growth momentum and profitability. This article breaks down the numbers,...
Nuvation Bio has surged, even as an insider sold a meaningful stake. This piece breaks down what the move means, how ...